| Whole series (n = 87) | Auto-HSCT (n = 56) | Allo-HSCT (n = 31) | p value | |
|---|---|---|---|---|
| Age, median (range) | 57 (17-72) | 60 (39-69) | 49 (17-72) | 0.008 |
| Diagnosis: | <0.001 | |||
| LNH | 13 (15%) | 11 (20%) | 2 (7%) | |
| MM | 41 (47%) | 41 (73%) | 0 | |
| AL | 22 (26%) | 0 | 22 (71%) | |
| Others | 11 (12%) | 4 (7%) | 7 (22%) | |
| Time from HSCT to vaccination: | 0.003 | |||
| <12 months | 23 (26%) | 10 (18%) | 13 (42%) | |
| ≥12 months | 64 (74%) | 46 (82%) | 18 (58%) | |
| Active GvHD | 16/31 (52%) | - | 16 (52%) | - |
| Last year anti-CD20 therapy | 3 (3%) | 3 (5%) | 0 | 0.550 |
| B-lymphocyte count, median (range)/mm3 | 113.5 (0-1287) | 65 (0-728) | 210 (0-1287) | 0.043 |
| IgG < 700 mg/dL | 35 (41%) | 21 (38%) | 14 (45%) | 0.527 |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.